OPEN END TURBO CALL WARRANT - FRESENIUS MEDICAL CARE Share Price

Certificat

DE000UK5B513

Delayed Deutsche Boerse AG 07:16:18 26/06/2024 pm IST
1.58 EUR -0.63% Intraday chart for OPEN END TURBO CALL WARRANT - FRESENIUS MEDICAL CARE
Current month-18.04%
1 month-17.19%
Date Price Change
26/24/26 1.58 -0.63%
25/24/25 1.59 -3.05%
24/24/24 1.64 +5.81%
21/24/21 1.55 -7.19%
20/24/20 1.67 +2.45%

Delayed Quote Deutsche Boerse AG

Last update June 26, 2024 at 07:16 pm IST

More quotes

Static data

Product typeKnock-Out ohne Stop Loss
Buy / SellCALL
Underlying FRESENIUS MEDICAL CARE AG
Issuer UBS
WKN UK5B51
ISINDE000UK5B513
Date issued 29/07/2022
Strike 20.01
Maturity Unlimited
Parity 10 : 1
Emission price 1.94
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 3.03
Lowest since issue 0.71
Spread 0.01
Spread %0.63%

Company Profile

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.
Sector
-
More about the company

Ratings for Fresenius Medical Care AG

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Consensus: Fresenius Medical Care AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
35.67 EUR
Average target price
39.97 EUR
Spread / Average Target
+12.07%
Consensus